Literature DB >> 22484002

On- and off-exercise kinetics of cardiac output in response to cycling and walking in COPD patients with GOLD Stages I-IV.

M K Vasilopoulou1, I Vogiatzis, I Nasis, S Spetsioti, E Cherouveim, M Koskolou, E A Kortianou, Z Louvaris, G Kaltsakas, A Koutsoukou, N G Koulouris, M Alchanatis.   

Abstract

Exercise-induced dynamic hyperinflation and large intrathoracic pressure swings may compromise the normal increase in cardiac output (Q) in Chronic Obstructive Pulmonary Disease (COPD). Therefore, it is anticipated that the greater the disease severity, the greater would be the impairment in cardiac output during exercise. Eighty COPD patients (20 at each GOLD Stage) and 10 healthy age-matched individuals undertook a constant-load test on a cycle-ergometer (75% WR(peak)) and a 6min walking test (6MWT). Cardiac output was measured by bioimpedance (PhysioFlow, Enduro) to determine the mean response time at the onset of exercise (MRTon) and during recovery (MRToff). Whilst cardiac output mean response time was not different between the two exercise protocols, MRT responses during cycling were slower in GOLD Stages III and IV compared to Stages I and II (MRTon: Stage I: 45±2, Stage II: 65±3, Stage III: 90±3, Stage IV: 106±3s; MRToff: Stage I: 42±2, Stage II: 68±3, Stage III: 87±3, Stage IV: 104±3s, respectively). In conclusion, the more advanced the disease severity the more impaired is the hemodynamic response to constant-load exercise and the 6MWT, possibly reflecting greater cardiovascular impairment and/or greater physical deconditioning.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22484002     DOI: 10.1016/j.resp.2012.03.014

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  7 in total

1.  Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.

Authors:  Adriano R Tonelli; Laith Alkukhun; Vineesha Arelli; José Ramos; Jennie Newman; Kevin McCarthy; Bohdan Pichurko; Omar A Minai; Raed A Dweik
Journal:  Clin Transl Sci       Date:  2013-09-06       Impact factor: 4.689

Review 2.  Advances in the Evaluation of Respiratory Pathophysiology during Exercise in Chronic Lung Diseases.

Authors:  Denis E O'Donnell; Amany F Elbehairy; Danilo C Berton; Nicolle J Domnik; J Alberto Neder
Journal:  Front Physiol       Date:  2017-02-22       Impact factor: 4.566

3.  Effects of high- and moderate-intensity exercise on central hemodynamic and oxygen uptake recovery kinetics in CHF-COPD overlap.

Authors:  A Mazzuco; A S Souza; W M Medeiros; P A Sperandio; M C N Alencar; F F Arbex; J A Neder; A Borghi-Silva
Journal:  Braz J Med Biol Res       Date:  2020-02-14       Impact factor: 2.590

4.  Association Between the Predictors of Functional Capacity and Heart Rate Off-Kinetics in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Patrícia Faria Camargo; Luciana Ditomaso-Luporini; Luiz Carlos Soares de Carvalho; Cássia da Luz Goulart; Rayane Sebold; Polliana Batista Dos Santos; Meliza Goi Roscani; Audrey Borghi-Silva
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-08-12

5.  Exercise Capacity, Ventilatory Response, and Gas Exchange in COPD Patients With Mild to Severe Obstruction Residing at High Altitude.

Authors:  Mauricio Gonzalez-Garcia; Margarita Barrero; Dario Maldonado
Journal:  Front Physiol       Date:  2021-06-18       Impact factor: 4.566

6.  Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies.

Authors:  Naoki Mugii; Fujiko Someya
Journal:  Rheumatol Int       Date:  2018-05-14       Impact factor: 2.631

7.  Proportional Assist Ventilation Improves Leg Muscle Reoxygenation After Exercise in Heart Failure With Reduced Ejection Fraction.

Authors:  Audrey Borghi-Silva; Cassia da Luz Goulart; Cláudia R Carrascosa; Cristino Carneiro Oliveira; Danilo C Berton; Dirceu Rodrigues de Almeida; Luiz Eduardo Nery; Ross Arena; J Alberto Neder
Journal:  Front Physiol       Date:  2021-06-21       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.